Professor of Pediatrics
Abramson Research Center
3rd Floor - Room 302D
With extended training in Pediatric Hematology, Oncology and Stem Cell Transplantation at Fred Hutchinson Cancer Research Center, Dr. Kurre’s clinical work is now focused on children with bone marrow failure. He strives to provide excellence in care for families and patients across a wide spectrum of inherited and acquired conditions that lead to loss of blood formation. As a Physician Scientist, both clinical and scientific goals of his work are therefore directed at improving understanding and broadening treatment options for patients with bone marrow failure.
Dr. Kurre’s clinical interests focus on diagnosis and treatment of bone marrow failure and specifically on improving diagnostic and therapeutic capabilities. Advances in genomic technologies provide exciting opportunity to streamline the frequently extended diagnostic work up of children with bone marrow failure. He and colleagues at other institutions are spearheading efforts to leverage molecular technologies toward the development of tests that improve diagnostic certainty and timeliness of genetic bone marrow failure. They are also developing clinical trials to enhance treatment and post treatment surveillance options.
Dr. Kurre’s laboratory has longstanding expertise in Fanconi Anemia (FA), a rare inherited genetic condition with prominent hematologic complications. With a training background in transplantation and hematopoietic stem cell biology, he hopes to improve understanding of the progressive hematopoietic failure that occurs in patients with FA. In addition to preclinical vector development for stem cell gene therapy, his more recent studies aim to reveal the origins of bone marrow failure in FA before birth. Studies in murine models of FA indicate that a significant portion of hematopoietic stem cells are lost prenatally and during infancy. The lab is developing strategies that will ameliorate those losses, with the long term goal of reversing the successive erosion of the stem cell pool in children. Additional projects in the lab are focused on stem cell regulation by trafficking of extracellular vesicles in the bone marrow microenvironment.
- Definitive demonstration that hematopoietic deficits in Fanconi Anemia arise during development
- First description of the role of vesicle trafficking in the development of cytopenias in Acute myeloid leukemia
- The development of preclinical protocols that minimize stem cell losses during lentivector transduction of Fanconi Anemia hematopoietic stem cells
MD RWTH Aachen University Aachen, North Rhine- Doctorate Thesis
Westphalia, Germany 1991
American Society of Hematology 2001-Present
American Society of Pediatric Hematology Oncology 2003-Present
NAPAAC, North American Pediatric Aplastic Anemia 2013-Present
Consortium (Member, Steering Committee)
NAPAAC, North American Pediatric Aplastic Anemia 2017-Present
Consortium (Member, Executive Committee)
Judge, American Biomedical Research Conference for 2009
Minority Students Phoenix, Travel Award
Member, Editorial Board, "The Hematologist" 2011-2014
Hyundai Scholar, Hyundai 'Hope on Wheels' Foundation 2012
Member, Editorial Board, "Journal of Extracellular Vesicles" 2014
Hyundai Scholar, Hyundai 'Hope on Wheels' Foundation 2014-2017
Member, Editorial Board, Scientific Reports 2017-Present
Member, Editorial Board, Current Stem Cell Reports 2017
Hyundai Scholar, Hyundai 'Hope on Wheels' Foundation 2018
The unfolded protein response as a mechanism of AML drug resistance. St. Baldricks Foundation Research Grant. 9/2018-8/2019 (Peter Kurre, PI), $100,000 direct costs, 5% effort (Role in grant: PI). Thie major goal of this grant is to determine the role of the unfolded protein response in chemotherapy resistance among children with AML.
Mitotically Stable Lentiviral Episomes for Stem Cell Gene Therapy, NIH/NIDDKD, 1 R01 DK108048-01, 10/2015-09/2018 (Peter Kurre, PI), $157,500/annual direct costs, 15% effort (Role in grant: PI, will be transferred to CHOP) Currently in NCE
The major goal of this project is the design and preclinical performance testing of a non-integrating lentivector for stem cell gene therapy.
Hornick Noah I, Doron Ben, Abdelhamed Sherif, Huan Jianya, Harrington Christina A, Shen Rongkun, Cambronne Xiaolu A, Chakkaramakkil Verghese Santhosh, Kurre Peter: AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB. Science signaling 9(444): ra88, Sep 2016.
Chakkaramakkil Verghese Santhosh, Goloviznina Natalya A, Kurre Peter: Phenotypic correction of Fanconi anemia cells in the murine bone marrow after carrier cell mediated delivery of lentiviral vector. Stem cell research & therapy 7(1): 170, Nov 2016. PMCID: PMC5116221
Gagne Katelyn E, Ghazvinian Roxanne, Yuan Daniel, Zon Rebecca L, Storm Kelsie, Mazur-Popinska Magdalena, Andolina Laura, Bubala Halina, Golebiowska Sydonia, Higman Meghan A, Kalwak Krzysztof, Kurre Peter, Matysiak Michal, Niewiadomska Edyta, Pels Salley, Petruzzi Mary Jane, Pobudejska-Pieniazek Aneta, Szczepanski Tomasz, Fleming Mark D, Gazda Hanna T, Agarwal Suneet: Pearson marrow pancreas syndrome in patients suspected to have Diamond-Blackfan anemia. Blood 124(3): 437-40, Jul 2014. PMCID: PMC4102714
Yoon Young Me, Storm Kelsie J, Kamimae-Lanning Ashley N, Goloviznina Natalya A, Kurre Peter: Endogenous DNA Damage Leads to p53-Independent Deficits in Replicative Fitness in Fetal Murine Fancd2(-/-) Hematopoietic Stem and Progenitor Cells. Stem cell reports 7(5): 840-853, Nov 2016. PMCID: PMC5106485
Doron Ben, Abdelhamed S, Butler JT, Hashmi SK, Horton TM, Kurre P. Transmissible ER stress reconfigures the AML bone marrow compartment. Leukemia. 2018 Sep 11. doi: 10.1038/s41375-018-0254-2.